Prevalence of Clonal CDRIII DNA in Cell-Free Blood Samples From Patients With NHL and ALL at Diagnosis and During Treatment
| Time of Sample Collection . | NHL . | ALL . | Total . |
|---|---|---|---|
| At diagnosis (n = 36) | |||
| Clonal CDRIII product | 21 | 10 | 31 (86%) |
| No clonal CDRIII product | 5 | 0 | 5 (14%) |
| On or after treatment (n = 60) | |||
| Clonal CDRIII product | 13 | 12 | 25 (42%) |
| No clonal CDRIII product | 24 | 11 | 35 (58%) |
| Time of Sample Collection . | NHL . | ALL . | Total . |
|---|---|---|---|
| At diagnosis (n = 36) | |||
| Clonal CDRIII product | 21 | 10 | 31 (86%) |
| No clonal CDRIII product | 5 | 0 | 5 (14%) |
| On or after treatment (n = 60) | |||
| Clonal CDRIII product | 13 | 12 | 25 (42%) |
| No clonal CDRIII product | 24 | 11 | 35 (58%) |
Only patients who were informative by PCR for tumor-derived CDRIII DNA are shown. Serum or plasma of patients was either sampled at the time of diagnosis or samples were taken at various times during or after treatment.